Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020
October 22 2020 - 8:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell
therapy to treat cancer, will report financial results and provide
a business update for Q3 2020, before the U.S. markets open on
Thursday, November 5, 2020. Following the announcement, the Company
will host a live teleconference and webcast at 8:00 a.m.
EST (1:00 p.m. GMT) on the same day (details below).
The press release and the live webcast of the conference call
will be available in the investor section of Adaptimmune’s
corporate website at www.adaptimmune.com. An archive will be
available after the call at the same address.
To participate in the live conference call, please dial (833)
652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International).
After placing the call, please ask to be joined into the
Adaptimmune conference call and provide the confirmation code
(6183339).
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR® (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the SEC on August 6, 2020, and our other SEC
filings. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we
do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez — VP, Communications and Investor RelationsT:
+44 1235 430 583M: +44 7718 453
176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — Senior Director, Investor RelationsT: +1
215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2024 to May 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From May 2023 to May 2024